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K. Balogh,1 M. Széll,2 H. Polyánka,2 F. Pagani,3 E. Bussani,3 L. Kemény1,2 and J. Oláh1
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4.2.2 ⁄B-10 ⁄1-2010-0012 (Szeged, Hungary)





Background The major locus for melanoma predisposition is the cell cycle regula-
tory CDKN2A gene on chromosome 9p21. However, the frequency of germline
coding mutations of the CDKN2A gene is lower than expected in melanoma-prone
families linked to chromosome 9p21.
Objectives To investigate whether the rare IVS1+37 G ⁄C intronic mutation of the
CDKN2A gene, recently identified in a Hungarian melanoma-prone family, influ-
ences mRNA splicing regulation.
Methods CDKN2A minigenes containing the wild-type and the mutant intronic
sequence were created and transfected into HeLa cells with the aim of studying
the mRNA transcripts.
Results The results revealed the emergence of a differential splicing pattern from
the wild-type and the mutant minigene, suggesting that this mutation may alter
the splicing of CDKN2A primary mRNA and therefore might have a pathogenetic
role in familial melanoma.
Conclusions We believe that these results confirm the importance of the identifica-
tion and characterization of CDKN2A intronic mutations with a view to improving
our understanding of the pathogenesis, and explain why the frequency of germ-
line coding mutations of the CDKN2A gene is lower than expected in melanoma-
prone families linked to chromosome 9p21.
The major locus for melanoma predisposition is the cell cycle
regulatory CDKN2A gene on chromosome 9p21. In the last two
decades we have gained much information on the melanoma-
predisposing coding mutations of the gene;1,2 however, we
know much less about the role of its intronic mutations.3–7
The frequency of germline coding mutations of the CDKN2A
gene is lower than expected in melanoma-prone families linked
to chromosome 9p21; therefore identification and functional
characterization of the intronic variants may provide further
insight into the genetic determinants of malignant melanoma.
We report the detection and functional data on the possible
pathogenetic role of a rare intronic mutation of the CDKN2A
gene found in an extensive Hungarian family with familial
melanoma and atypical multiple mole (FAMMM) syndrome.
Patients and methods
Detailed analysis of the family tree revealed other types of
malignancies besides melanoma (Fig. 1). We recently detected
the IVS1+37 G ⁄C heterozygote intronic mutation of the
CDKN2A gene in the above-mentioned Hungarian melanoma-
prone family. Regarding the occurrence of atypical naevi
and ⁄or melanoma in nearly all family members carrying the
IVS1+37 G ⁄C mutation, along with the family history of man-
ifestation of other malignant tumours, we hypothesized that
the mutation may result in aberrant splicing and that the aber-
rant mRNA may play a pathogenetic role in the development
of melanoma. Unfortunately, the members of the melanoma-
prone Hungarian family declined to provide skin specimens to
facilitate the in vivo identification of the alternative CDKN2A
splice variants. We therefore conducted in vitro functional anal-
ysis to investigate whether the IVS1+37 G ⁄C intronic mutation
had any effect on splicing regulation. Two minigenes were
constructed: one that harboured the wild-type and one that
harboured the mutant allele of CDKN2A (Fig. 2a).
For investigation of the effects of the mutation on splicing,
HeLa cells were transfected with the wild-type and mutant
minigenes. Transfection was carried out with the TurboFect
reagent (Fermentas, Vilnius, Lithuania), the cells were cultured
for 24 h and total RNA was isolated through the use of TRI
Reagent Solution (Applied Biosystems, Foster City, CA,
U.S.A.). Reverse transcription was performed with the iScript
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cDNA Synthesis Kit (BioRad, Hercules, CA, U.S.A.) and the
splice variants were detected with polymerase chain reaction
(PCR), T7 and Sp6 primers being used for the pcDNA3 vector:
in this way, the amplification of internal CDKN2A transcripts
could be avoided. PCR reactions were performed in GoTaq
Hot Start mix (Promega, Madison, WI, U.S.A.). The PCR prod-
ucts were run on 2% agarose gel and photographed, and the
bands were purified from the gel and sequenced (Fig. 2b).
Sequences were analysed with the BioEdit program (http://
www.mbio.ncsu.edu/BioEdit/bioedit.html).
Results
The mutation is situated in intron 1 (IVS1+37 G ⁄C) and has
so far been mentioned twice in case reports: in a FAMMM
pedigree and in a single patient with primary melanoma, both
from Italy,5,6 and summarized in a review paper by Orlow
et al.8 In silico assays reported in one of these papers did not
reveal any predicted defects in mRNA processing caused by
the mutation and it was therefore qualified as a mutation of
unknown significance.
Our sequence analysis involving the comparison of the
mRNA arising from the wild-type and that from the mutant
minigene revealed a differential splicing pattern (Fig. 2b): the
shorter band corresponds to a 339-nt CDKN2A sequence as a
result of normal splicing, while the 459-nt upper band relates
to an extended alternative splice product formed by the add-
ition of a 120-nt sequence of intron 1 as an exon (Fig. 2c).
This result was identically obtained in three independent
transfection experiments on HeLa cells, suggesting that the
A G G GT C C C C C C CCA TN
Fig 1. Family tree of the extensive melanoma-
prone Hungarian family and detection of the
IVS1+37 G ⁄C CDKN2A intronic mutation.
Direct sequencing of the CDKN2A gene was
performed on specimens from seven members
of the family (II ⁄3, II ⁄5, III ⁄4, III ⁄6, IV ⁄6,
IV ⁄8 and IV ⁄9) in branches B and C. Members
in branch A were not available for genetic
screening. Most of the family members
carrying the IVS1+37 G ⁄C mutation developed
atypical naevi and ⁄or melanoma. However,
collateral history revealed that of family
members of branch A, individual III ⁄2 died
from lung carcinoma and individual IV ⁄1
developed prostate carcinoma at a young age.
(a)
(b) (c)
Fig 2. In vitro minigene approach for studying the effects of the IVS1+37 G ⁄C CDKN2A intronic mutation on splicing regulation. (a) Two regions
of the CDKN2A gene (Acc. No. AL449423.14; 5¢ insert: nt 65456–64678 and 3¢ insert: nt 62359–61715) were amplified from the genomic DNA
of patient II ⁄5, who carried the IVS1+37 G ⁄C CDKN2A intronic mutation in a heterozygous form, and were cloned consequently into the pcDNA3
vector (Life Technologies, Carlsbad, CA, U.S.A.). The first insert of the minigene construct included a 38-nt sequence of exon 1a and a 741-nt
sequence of the downstream intron (wild-type and mutant versions), while the second insert consisted of a 410-nt sequence of intron 1 and a
236-nt sequence of exon 2. The entire length of the insert was 1424 nt, lacking a 2318-nt deep intronic sequence of the CDKN2A gene (Acc. No.
AL449423.14; nt 64677–62360). (b) Reverse transcription–polymerase chain reaction, in which the mRNA arising from the wild-type minigene
(wt) was compared with that from the mutant (mut), revealed a differential splicing pattern. (c) Sequence analysis demonstrated that the IVS1+37
G ⁄C mutation resulted in the recognition of cryptic splice sites in intron 1 and thus a 120-nt extension of the mRNA product.
 2012 The Authors
BJD  2012 British Association of Dermatologists 2012 167, pp131–133
132 CDKN2A intronic mutation, K. Balogh et al.
in vitro minigene approach applied was suitable for studying
the effects of the identified intronic IVS1+37 G ⁄C mutation
on splicing.
Discussion
Whether the aberrant mRNA is stable and translated or not,
our results indicate that it may play a pathogenetic role in
familial melanoma. If the aberrant mRNA were translated, the
inclusion of the cryptic exon would result in a frameshift and
an early stop codon would change the structure of the p16
protein; if the aberrant mRNA were not stable, it would
reduce the quantity of functional p16 indirectly.
In conclusion, the segregation of the IVS1+37 G ⁄C intronic
CDKN2A mutation with FAMMM in the extensive melanoma-
prone family and the results of our in vitro minigene experi-
ments suggest that this mutation may have a pathogenetic
role, most likely involving alteration of the splicing of the
CDKN2A primary mRNA. Besides CDKN2A coding mutations,
intronic mutations of the loci may contribute to melanoma
susceptibility and identification of these mutations would
facilitate our understanding of why the frequency of germ-
line coding mutations of the CDKN2A gene is lower than
expected in melanoma-prone families linked to chromosome
9p21.
What’s already known about this topic?
• The major locus for melanoma predisposition is the
cell cycle regulatory CDKN2A gene on chromosome
9p21.
• However, the frequency of germline coding mutations
of the CDKN2A gene is lower than expected in
melanoma-prone families linked to chromosome 9p21.
What does this study add?
• We report the detection and functional data on the pos-
sible pathogenetic role of a rare IVS1+37 G ⁄C intronic
mutation of the CDKN2A gene found in a Hungarian
melanoma-prone family.
• This mutation most likely involves alteration of the
splicing of the CDKN2A primary mRNA.
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